Agenus Inc. (NASDAQ:AGEN – Get Rating) – Stock analysts at B. Riley issued their Q1 2023 earnings per share (EPS) estimates for shares of Agenus in a research note issued to investors on Tuesday, March 14th. B. Riley analyst M. Mamtani forecasts that the biotechnology company will post earnings per share of ($0.30) for the quarter. The consensus estimate for Agenus’ current full-year earnings is ($0.74) per share. B. Riley also issued estimates for Agenus’ Q2 2023 earnings at ($0.29) EPS, Q3 2023 earnings at ($0.27) EPS, Q4 2023 earnings at ($0.27) EPS, FY2023 earnings at ($1.03) EPS and FY2024 earnings at ($1.06) EPS.
Several other equities analysts have also weighed in on the company. StockNews.com initiated coverage on Agenus in a report on Thursday. They set a “sell” rating on the stock. EF Hutton Acquisition Co. I restated a “buy” rating and set a $8.30 price target on shares of Agenus in a research note on Wednesday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $8.00 price objective on shares of Agenus in a report on Tuesday, February 28th. One research analyst has rated the stock with a sell rating and three have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $7.10.
Agenus Stock Down 7.1 %
Institutional Inflows and Outflows
A number of hedge funds have recently added to or reduced their stakes in the company. State Street Corp lifted its holdings in shares of Agenus by 30.9% during the second quarter. State Street Corp now owns 23,243,261 shares of the biotechnology company’s stock worth $45,092,000 after purchasing an additional 5,484,637 shares during the period. Vanguard Group Inc. increased its position in shares of Agenus by 7.9% during the third quarter. Vanguard Group Inc. now owns 22,851,170 shares of the biotechnology company’s stock worth $46,845,000 after acquiring an additional 1,673,615 shares in the last quarter. BlackRock Inc. increased its position in shares of Agenus by 2.4% during the third quarter. BlackRock Inc. now owns 21,562,167 shares of the biotechnology company’s stock worth $44,202,000 after acquiring an additional 510,466 shares in the last quarter. Artal Group S.A. boosted its holdings in Agenus by 262.5% during the fourth quarter. Artal Group S.A. now owns 14,500,000 shares of the biotechnology company’s stock worth $34,800,000 after purchasing an additional 10,500,000 shares during the last quarter. Finally, Point72 Asset Management L.P. boosted its stake in Agenus by 6.6% in the fourth quarter. Point72 Asset Management L.P. now owns 8,923,300 shares of the biotechnology company’s stock valued at $21,416,000 after acquiring an additional 551,100 shares during the last quarter. 53.81% of the stock is owned by institutional investors.
Agenus Company Profile
Agenus, Inc is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H.
Recommended Stories
- Get a free copy of the StockNews.com research report on Agenus (AGEN)
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
- Europe Raises Interest Rates, Should the Fed Follow?
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.
